Evommune, Inc. Increase (Decrease) in Accrued Liabilities
Evommune, Inc. (EVMN) reported Increase (Decrease) in Accrued Liabilities of $1.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Evommune, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $5.95M, a 361.91% increase year-over-year.
- Evommune, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.81M.
- Evommune, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $4.30M.
- Evommune, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$666.00K.
- Evommune, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $2.82M, a 4.22% increase from fiscal 2024.
- Evommune, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $2.70M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.14M 10-Q · filed 2026-08-06 | $5.44M derived: sum of 3 quarters · filed 2026-08-06 | $4.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.81M 10-Q · filed 2026-05-07 | -$516.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.18M derived: sum of 3 quarters · filed 2026-05-07 | $107.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.63M derived: sum of 2 quarters · filed 2026-03-05 | $4.92M derived: sum of 3 quarters · filed 2026-08-06 | $2.82M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$666.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | $623.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.48M 10-Q · filed 2025-12-11 | -$1.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$813.00K 10-Q · filed 2026-08-06 | -$953.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$2.10M 10-Q · filed 2026-05-07 | -$2.24M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.70M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $2.84M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |